Johnson & Johnson (JNJ) : Kelly Lawrence W Associates Incca scooped up 40 additional shares in Johnson & Johnson during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 133,725 shares of Johnson & Johnson which is valued at $16,477,595.Johnson & Johnson makes up approximately 3.85% of Kelly Lawrence W Associates Incca’s portfolio.
Other Hedge Funds, Including , Aureus Asset Management reduced its stake in JNJ by selling 999 shares or 3.8% in the most recent quarter. The Hedge Fund company now holds 25,305 shares of JNJ which is valued at $3,118,082. Johnson & Johnson makes up approx 0.64% of Aureus Asset Management’s portfolio.Dubuque Bank Trust Co boosted its stake in JNJ in the latest quarter, The investment management firm added 1,771 additional shares and now holds a total of 28,558 shares of Johnson & Johnson which is valued at $3,518,917. Johnson & Johnson makes up approx 0.65% of Dubuque Bank Trust Co’s portfolio.Texas Yale Capital Corp. reduced its stake in JNJ by selling 87 shares or 0.21% in the most recent quarter. The Hedge Fund company now holds 42,009 shares of JNJ which is valued at $5,176,349. Johnson & Johnson makes up approx 0.49% of Texas Yale Capital Corp.’s portfolio.Hirtle Callaghan Co reduced its stake in JNJ by selling 334 shares or 2.12% in the most recent quarter. The Hedge Fund company now holds 15,397 shares of JNJ which is valued at $1,907,688. Johnson & Johnson makes up approx 0.34% of Hirtle Callaghan Co’s portfolio.Bridge Creek Capital Management reduced its stake in JNJ by selling 805 shares or 2.05% in the most recent quarter. The Hedge Fund company now holds 38,433 shares of JNJ which is valued at $4,812,965. Johnson & Johnson makes up approx 2.78% of Bridge Creek Capital Management’s portfolio.
Johnson & Johnson closed down -0.26 points or -0.22% at $119.08 with 45,51,792 shares getting traded on Thursday. Post opening the session at $119.19, the shares hit an intraday low of $118.6 and an intraday high of $119.39 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Johnson & Johnson reported $1.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 19, 2016. Analyst had a consensus of $1.68. The company had revenue of $18482.00 million for the quarter, compared to analysts expectations of $17985.80 million. The company’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.71 EPS.
Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by UBS on Jul 20, 2016 to “Buy”, Firm has raised the Price Target to $ 137 from a previous price target of $126 .Company shares were Reiterated by RBC Capital Mkts on Jul 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 133 from a previous price target of $125 .Standpoint Research Initiated Johnson & Johnson on May 20, 2016 to “Sell”, Price Target of the shares are set at $94.
Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.